Take This Into Account Before Investing in NVAX

Novavax logged a -0.3% change during today's morning session, and is now trading at a price of $7.64 per share.

Novavax returned losses of -85.7% last year, with its stock price reaching a high of $76.77 and a low of $5.61. Over the same period, the stock underperformed the S&P 500 index by -86.0%. As of April 2023, the company's 50-day average price was $7.63. Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. Based in Gaithersburg, MD, the mid-cap Health Care company has 1,992 full time employees. Novavax has not offered a dividend during the last year.

The Business Is Unprofitable and Its Balance Sheet Is Highly Leveraged:

2019-12-31 2020-12-31 2021-12-31 2022-12-31
Revenue (MM) $19 $476 $1,146 $1,599
Revenue Growth n/a 2448.48% 141.02% 39.49%
Gross Margins n/a n/a n/a 43.6%
Gross Margins Growth n/a n/a n/a n/a
Operating Margins -694.4% -87.6% -147.1% -40.3%
Operating Margins Growth n/a 87.38% -67.92% 72.6%
Net Margins -711.04% -87.94% -152.12% -41.15%
Net Margins Growth n/a 87.63% -72.98% 72.95%
Earnings Per Share -$5.51 -$7.27 -$23.44 -$8.54
EPS Growth n/a -31.94% -222.42% 63.57%
Diluted Shares (MM) 24 58 74 86
Free Cash Flow (MM) -$138 -$97 $265 -$509
FCF Growth n/a 29.84% 373.21% -291.71%
Capital Expenditures (MM) -$2 -$55 -$57 -$93
LT Debt to Equity -1.72 0.51 -0.92 -0.26

Novavax does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at $-1.7. The average P/E ratio for the Health Care sector is 24.45.

Novavax Has an Average Rating of Hold:

The 5 analysts following Novavax have set target prices ranging from $10.0 to $110.0 per share, for an average of $41.8 with a hold rating. As of April 2023, the company is trading -81.7% away from its average target price, indicating that there is an analyst consensus of strong upside potential.

Novavax has an unusually large proportion of its shares sold short because 39.8% of the company's shares are sold short. Institutions own 61.5% of the company's shares, and the insider ownership rate stands at 0.44%, suggesting a small amount of insider investors. The largest shareholder is the Vanguard Group, Inc., whose 10% stake in the company is worth $67,617,372.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.